Abstract 208P
Background
V-set and immunoglobulin domain containing 1 (VSIG1) is known as a gastric-related biomarker. Few specific data are known about its positivity in hepatocellular carcinoma (HCC). The aim of the study is to examine the possible clinical importance of VSIG1 in HCC.
Methods
In 217 HCC samples, the expression of VSIG1 (polyclonal; Sigma-Aldrich) was checked using immunohistochemistry (IHC) methods. The obtained data were correlated with the clinico-pathological parameters.
Results
VSIG1 was highly expressed in 90 cases (41.47%). Low positivity was seen in 23 cases (10.60%), the other 104 cases (47.93%) being negative for VSIG1. The VSIG1 positivity proved to be significantly downregulated in pT3 stages compared to pT1/2 stages, with a more loss of expression in scirrhous-type HCCs (<0.0001) that also showed positivity for vimentin. VSIG1 positivity proved to be an indicator of a longer overall survival, compared with negative cases (p=0.04).
Conclusions
The cell-cell adhesion molecule VSIG1 might influence hepatocarcinogenesis. Its downregulation might be considered a negative prognostic indicator.
Legal entity responsible for the study
George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Romania.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.